Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

674

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Acute Schizophrenia
Interventions
DRUG

OPC-34712

Higher dose tablet, once daily, for six weeks,

DRUG

OPC-34712

Middle dose tablet, once daily, for six weeks

DRUG

OPC-34712

Lower dose tablet, once daily, for six weeks

DRUG

Placebo

Placebo, once daily, for six weeks

Trial Locations (60)

110

Taipei

249

New Taipei City

333

Taoyuan District

802

Kaohsiung City

1000

Manila

1229

Makati City

1553

Mandaluyong

6000

Cebu City

8000

Davano City

10000

Zagreb

10090

Zagreb

14215

Buffalo

33161

North Miami

33162

North Miami

38119

Memphis

39232

Flowood

40447

Taichung

51000

Rijeka

63118

St Louis

64060

Monterrey

Monterrey

66212

Overland Park

70629

Lake Charles

71104

Shreveport

72201

Little Rock

72764

Springdale

75243

Dallas

77007

Houston

78218

San Luis Potosí City

78756

Austin

82606

Bratislava

90660

Pico Rivera

90813

Long Beach

92025

Escondido

92102

San Diego

92868

Orange

97201

Bojnice

97912

Rimavská Sobota

117152

Moscow

119991

Moscow

142601

Moscow Region

163530

Arkhangelsk

185000

Petrozavodsk

188357

Village Nikolskoe

190005

Saint Petersburg

190121

Saint Petersburg

192019

Saint Petersburg

194214

Saint Petersburg

197341

Saint Petersburg

410060

Saratov

443016

Samara

603155

Nizhny Novgorod

634014

Tomsk

00000

Bogotá

Medellín

Pereira

01030

Col. Florida

05300

Mexico City

07101

Michalovace

04801

Rožňava

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01393613 - Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia | Biotech Hunter | Biotech Hunter